

INcidence of VENous Thromboembolism after acute stroke in China

Submission date 28/04/2007	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 06/06/2007	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 19/10/2021	Condition category Circulatory System	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Wang Yongjun

Contact details
Tiantan Hospital
Beijing
China
100050
+86 (0)10 6701 3383
zhg_doc@yahoo.com

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
INVENT-10

Study information

Scientific Title

Incidence of Venous Thromboembolism after acute stroke in China

Acronym

INVENT-China

Study objectives

1. Incidence of venous thromboembolism after acute stroke in China was lower than in western countries
2. Risk factors are different between Venous Thromboembolism (VTE) and non-VTE
3. Anticoagulation and neurological rehabilitation can reduce the incidence

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approval received from the Tiantan Hospital Ethics Committee on the 29th November 2006 (ref: 7).

Study design

Multicentre observational, prospective, nested case-control study.

Primary study design

Observational

Secondary study design

Case-control study

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet**Health condition(s) or problem(s) studied**

Venous thromboembolism

Interventions

Group A: stroke inpatients with Deep Venous Thrombosis (DVT) during follow up

Group B: stroke inpatients without DVT during follow up

DVT will be determined by complete-comprehensive ultrasound sonography two weeks (14 ± 3 days) after stroke onset.

Possible risk factors will be compared between group A and group B, these will include:

1. stroke subtype
2. NIHSS
3. Medical history
4. Complications

5. High Density Lipoprotein (HDL)
6. Low Density Lipoprotein (LDL)
7. Triglycerides (TG)

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Incidence of Deep Venous Thrombosis after acute stroke in China, measured at two weeks (14 ± 3 days) after stroke onset.

Secondary outcome measures

Predict model of VTE in acute stroke in China, measured at two weeks (14 ± 3 days) after stroke onset.

Overall study start date

08/05/2007

Completion date

08/10/2007

Eligibility**Key inclusion criteria**

1. Older than 18
2. Acute stroke patients within seven days
3. Identified by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI)
4. National Institutes of Health Stroke Scale (NIHSS) item-six more than one

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Not Specified

Target number of participants

1882

Key exclusion criteria

1. Transient Ischaemic Attacks (TIAs)
2. Sub-Arachnoid Haemorrhage (SAH)

- 3. Tumour
- 4. Medical history of VTE

Date of first enrolment

08/05/2007

Date of final enrolment

08/10/2007

Locations

Countries of recruitment

China

Study participating centre

Tiantan Hospital

Beijing

China

100050

Sponsor information

Organisation

Beijing Tiantan Hospital (China)

Sponsor details

c/o Professor Yongjun Wang

Affiliated Hospital of Capital Medical University

Beijing

China

100050

Sponsor type

Hospital/treatment centre

ROR

<https://ror.org/003regz62>

Funder(s)

Funder type

Industry

Funder Name

Glaxosmithkline (China)

Alternative Name(s)

GlaxoSmithKline plc., GSK plc., GSK

Funding Body Type

Government organisation

Funding Body Subtype

For-profit companies (industry)

Location

United Kingdom

Funder Name

Beijing Munciple Science and Technology Commission (China)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration